JP2024512470A5 - - Google Patents
Info
- Publication number
- JP2024512470A5 JP2024512470A5 JP2023556962A JP2023556962A JP2024512470A5 JP 2024512470 A5 JP2024512470 A5 JP 2024512470A5 JP 2023556962 A JP2023556962 A JP 2023556962A JP 2023556962 A JP2023556962 A JP 2023556962A JP 2024512470 A5 JP2024512470 A5 JP 2024512470A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acid
- peptide
- tmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163163270P | 2021-03-19 | 2021-03-19 | |
| US63/163,270 | 2021-03-19 | ||
| PCT/US2022/020819 WO2022197971A1 (en) | 2021-03-19 | 2022-03-17 | T-cell modulatory polypeptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512470A JP2024512470A (ja) | 2024-03-19 |
| JP2024512470A5 true JP2024512470A5 (OSRAM) | 2025-03-25 |
Family
ID=83320830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023556962A Pending JP2024512470A (ja) | 2021-03-19 | 2022-03-17 | Ｔ細胞調節ポリペプチド及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240067700A1 (OSRAM) |
| EP (1) | EP4308143A4 (OSRAM) |
| JP (1) | JP2024512470A (OSRAM) |
| CN (1) | CN116981470A (OSRAM) |
| AU (1) | AU2022238389A1 (OSRAM) |
| CA (1) | CA3212382A1 (OSRAM) |
| WO (1) | WO2022197971A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102760578B1 (ko) | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| TW201920249A (zh) | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| EP4211149A4 (en) | 2020-09-09 | 2024-10-09 | Cue Biopharma, Inc. | MULTIMERIC POLYPEPTIDES MODULATING MHC CLASS II T CELLS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS (T1D) AND METHODS OF USE THEREOF |
| WO2024264004A2 (en) * | 2023-06-23 | 2024-12-26 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| WO2024264007A2 (en) * | 2023-06-23 | 2024-12-26 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| CN117024601A (zh) * | 2023-07-14 | 2023-11-10 | 合肥工业大学 | 一种宣威火腿源抗氧化肽及其制备方法和活性测定方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7138370B2 (en) * | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| ES2784261T3 (es) * | 2014-11-26 | 2020-09-23 | Us Health | Receptores de células T anti-KRAS mutado |
| KR102760578B1 (ko) * | 2016-12-22 | 2025-02-03 | 큐 바이오파마, 인크. | T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법 |
| TW201920249A (zh) * | 2017-09-07 | 2019-06-01 | 美商信號生物製藥公司 | 具有結合位點之t細胞調節多聚體多肽及其使用方法 |
| EP3678677A4 (en) * | 2017-09-07 | 2021-06-16 | Cue Biopharma, Inc. | Antigen-presenting polypeptides and methods of use thereof |
| TWI856047B (zh) * | 2018-12-19 | 2024-09-21 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| MX2021012004A (es) * | 2019-03-30 | 2021-11-04 | Biontech Us Inc | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. |
| AU2020282736B2 (en) * | 2019-05-29 | 2025-10-30 | Cue Biopharma, Inc. | Multimeric T-cell modulatory polypeptides and methods of use thereof |
| JP2022536581A (ja) * | 2019-06-19 | 2022-08-18 | キュー バイオファーマ， インコーポレイテッド | 多量体ｔ細胞調節性ポリペプチド及びその使用方法 |
| WO2021055594A1 (en) * | 2019-09-20 | 2021-03-25 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| WO2021172596A1 (ja) * | 2020-02-28 | 2021-09-02 | 国立大学法人金沢大学 | 免疫制御法、免疫制御用核酸組成物およびその用途 |
-
2022
- 2022-03-17 CA CA3212382A patent/CA3212382A1/en active Pending
- 2022-03-17 EP EP22772233.7A patent/EP4308143A4/en not_active Withdrawn
- 2022-03-17 AU AU2022238389A patent/AU2022238389A1/en not_active Abandoned
- 2022-03-17 CN CN202280021349.6A patent/CN116981470A/zh active Pending
- 2022-03-17 JP JP2023556962A patent/JP2024512470A/ja active Pending
- 2022-03-17 WO PCT/US2022/020819 patent/WO2022197971A1/en not_active Ceased
-
2023
- 2023-08-16 US US18/234,640 patent/US20240067700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548472A5 (OSRAM) | ||
| JP2020514375A5 (OSRAM) | ||
| CN110325205B (zh) | T细胞调节性多聚体多肽及其使用方法 | |
| JP2022536581A5 (OSRAM) | ||
| JP2023527049A5 (OSRAM) | ||
| JP2022534846A5 (OSRAM) | ||
| GB2611448A (en) | Polypeptide useful in adoptive cell therapy | |
| Maher | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells | |
| CN110914308A (zh) | 改进的双特异性多肽分子 | |
| JP2020511949A5 (OSRAM) | ||
| WO2019051126A4 (en) | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof | |
| JP2017519491A5 (OSRAM) | ||
| JP2023526723A5 (OSRAM) | ||
| JP2022515330A5 (OSRAM) | ||
| JP2024518680A5 (OSRAM) | ||
| WO2018199595A1 (ko) | 4-1bbl 변이체 및 이를 포함하는 융합 단백질 | |
| US20230201335A1 (en) | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | |
| JP2022519713A (ja) | Ｃａｒ操作されたｔ細胞およびサイトカインを含む治療 | |
| JP2024541334A5 (OSRAM) | ||
| US12180297B2 (en) | ATP-dependent agonists of immune cells function as anticancer agents | |
| JP2022526194A5 (OSRAM) | ||
| US20230218731A1 (en) | Antigen Presenting Polypeptide Complexes and Methods of Use Thereof | |
| JP2024534783A5 (OSRAM) | ||
| AU678144B2 (en) | ICAMs immunoglobulin constant region soluble fusion proteins | |
| JP2023541132A (ja) | 免疫細胞におけるアダプターの誘導性発現のための系 |